Guizhou Yibai Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of June 2025: 0.49%

Guizhou Yibai Pharmaceutical Co Ltd (600594) has an Asset Resilience Ratio of 0.49% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore Guizhou Yibai Pharmaceutical Co Ltd assets under control for the complete picture of this company's asset base.

Liquid Assets

CN¥20.00 Million
≈ $2.93 Million USD Cash + Short-term Investments

Total Assets

CN¥4.05 Billion
≈ $592.98 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2024–2024)

This chart shows how Guizhou Yibai Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See how leveraged is Guizhou Yibai Pharmaceutical Co Ltd's balance sheet to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Guizhou Yibai Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Guizhou Yibai Pharmaceutical Co Ltd (600594) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥20.00 Million 0.49%
Total Liquid Assets CN¥20.00 Million 0.49%

Asset Resilience Insights

  • Limited Liquidity: Guizhou Yibai Pharmaceutical Co Ltd maintains only 0.49% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Guizhou Yibai Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Guizhou Yibai Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
Drug Manufacturers - Specialty & Generic 0.16%
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Ajanta Pharma Limited
NSE:AJANTPHARM
Drug Manufacturers - Specialty & Generic 14.99%
Kangmei Pharmaceutical Co Ltd
SHG:600518
Drug Manufacturers - Specialty & Generic 0.00%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424
Drug Manufacturers - Specialty & Generic 2.09%
Dezhan HealthCare Co Ltd
SHE:000813
Drug Manufacturers - Specialty & Generic 0.15%

Annual Asset Resilience Ratio for Guizhou Yibai Pharmaceutical Co Ltd (2024–2024)

The table below shows the annual Asset Resilience Ratio data for Guizhou Yibai Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.49% CN¥20.00 Million
≈ $2.93 Million
CN¥4.10 Billion
≈ $599.92 Million
--
pp = percentage points

About Guizhou Yibai Pharmaceutical Co Ltd

SHG:600594 China Drug Manufacturers - Specialty & Generic
Market Cap
$409.07 Million
CN¥2.80 Billion CNY
Market Cap Rank
#13553 Global
#4147 in China
Share Price
CN¥3.53
Change (1 day)
-1.40%
52-Week Range
CN¥3.45 - CN¥5.06
All Time High
CN¥19.64
About

Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. It offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, lyophilized powder injections, pills, and oral solutions in the areas of tumor system, cerebrovascular, respiratory system, rheumatic bone, digestive system… Read more